Quoin Pharmaceuticals, Ltd. (QNRX) Bundle
An Overview of Quoin Pharmaceuticals, Ltd. (QNRX)
General Summary of Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals Ltd. (“Quoin Ltd.”), formerly known as Cellect Biotechnology Ltd., is a clinical stage specialty pharmaceutical company focused on developing therapeutic products for rare and orphan diseases. The company was established following the merger with Quoin Pharmaceuticals, Inc., which was incorporated in Delaware on March 5, 2018. This merger was completed on October 28, 2021, leading to the name change of Cellect to Quoin Pharmaceuticals Ltd.
Quoin's initial focus is on developing products utilizing proprietary and in-licensed drug delivery technologies to address rare skin diseases. Its lead product, QRX003, is a topical lotion designed to treat Netherton Syndrome (NS), a rare genetic condition. QRX003 is under development and is currently involved in two clinical studies in the U.S., with patient dosing having commenced in December 2022 for the first study and March 2023 for the second study. The company also aims to develop QRX004 for Recessive Dystrophic Epidermolysis Bullosa (RDEB), and has entered into research agreements with the Queensland University of Technology (QUT) for additional product developments.
As of 2024, Quoin Pharmaceuticals has not yet commercialized any products nor generated revenue.
Company's Financial Performance in the Latest Financial Reports
For the nine months ended September 30, 2024, Quoin Pharmaceuticals reported a net loss of approximately $6.65 million, compared to a net loss of $6.64 million for the same period in 2023, reflecting a slight increase in losses of $14,503. The company's total operating expenses for this period were approximately $7.12 million, down from $7.16 million in the previous year.
The breakdown of operating expenses is as follows:
| Operating Expenses | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| General and Administrative | $4,590,936 | $4,685,241 | $(94,305) |
| Research and Development | $2,532,468 | $2,475,596 | $56,872 |
| Total Operating Expenses | $7,123,404 | $7,160,837 | $(37,433) |
Quoin Pharmaceuticals incurred approximately $1.17 million in research and development expenses for the three months ended September 30, 2024, which is an increase of 54% compared to $758,759 in the same period in 2023. This increase is primarily attributed to heightened expenditures related to its development programs.
As of September 30, 2024, the company reported cash and cash equivalents totaling approximately $10.31 million, alongside investments in marketable securities. The net cash used in operating activities was approximately $5.62 million, an increase from $4.64 million in 2023.
Introduction to Quoin Pharmaceuticals as a Leader in the Industry
Quoin Pharmaceuticals is positioned as a clinical-stage leader in the specialty pharmaceutical sector, focusing on rare and orphan diseases. The company is dedicated to addressing unmet medical needs through innovative drug delivery technologies. Its lead product, QRX003, represents a significant advancement in the treatment landscape for Netherton Syndrome, which currently lacks effective therapies.
With ongoing clinical studies and an active pipeline, Quoin Pharmaceuticals is poised to make a meaningful impact in the biopharmaceutical industry. The company's commitment to research and development, coupled with strategic partnerships, underscores its potential to emerge as a key player in the treatment of rare skin diseases.
To understand more about Quoin Pharmaceuticals' strategies and successes, further exploration into its detailed financial reports and product development initiatives is recommended.
Mission Statement of Quoin Pharmaceuticals, Ltd. (QNRX)
Mission Statement Overview
The mission statement of Quoin Pharmaceuticals, Ltd. (QNRX) is a critical guiding framework that encapsulates the company's purpose and objectives. It emphasizes the commitment to developing innovative therapeutics for patients with rare and orphan diseases, driving the company's strategic initiatives and operational priorities.
Core Component 1: Commitment to Innovation
Quoin Pharmaceuticals is dedicated to advancing medical science through innovation. The company invests significantly in research and development, with approximately $2.53 million allocated to R&D activities for the nine months ended September 30, 2024, reflecting a 2% increase from $2.48 million in the same period of 2023 .
The lead asset, QRX003, is currently in late-stage clinical development, with clinical trials involving a randomized, double-blind assessment of its efficacy. The expected costs for clinical studies are approximately $4.4 million .
Core Component 2: Patient-Centric Approach
Quoin Pharmaceuticals prioritizes patient needs in its mission, aiming to provide effective and accessible treatments. The company’s ongoing clinical studies for QRX003 focus on conditions like Netherton Syndrome, aiming to improve the quality of life for patients suffering from rare diseases. The company has opened five clinical sites in the U.S. for patient recruitment .
As of September 30, 2024, Quoin had approximately $10.3 million in cash and cash equivalents, which supports its patient-centric initiatives and the development of new therapies .
Core Component 3: Commitment to Quality and Compliance
Quality and compliance are fundamental to Quoin’s mission. The company adheres to rigorous regulatory standards, evidenced by its open Investigational New Drug (IND) application with the FDA for QRX003 . The total operating expenses for the nine months ended September 30, 2024, were approximately $7.12 million, indicating a robust investment in maintaining high standards .
Moreover, the company’s licensing agreement with Skinvisible Pharmaceuticals involves a one-time license fee of $1 million and royalties on net sales, ensuring compliance with intellectual property standards .
| Financial Metric | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Research and Development Expenses | $2,532,468 | $2,475,596 | +2% |
| Total Operating Expenses | $7,123,404 | $7,160,837 | -0.5% |
| Net Loss | $(6,651,198) | $(6,636,695) | +0.2% |
| Cash and Cash Equivalents | $10,307,000 | Not Available | N/A |
| License Fee to Skinvisible | $1,000,000 | Not Available | N/A |
Vision Statement of Quoin Pharmaceuticals, Ltd. (QNRX)
Vision Statement Overview
The vision statement of Quoin Pharmaceuticals, Ltd. (QNRX) is centered around the commitment to develop innovative treatments for rare and orphan diseases. The company aims to be a leader in the specialty pharmaceutical industry by leveraging proprietary technologies and research collaborations.
Commitment to Innovation
Quoin Pharmaceuticals is dedicated to advancing science through continuous innovation. This commitment is exemplified by their leading product, QRX003, which is in late-stage clinical development targeting Netherton Syndrome. As of September 30, 2024, the company has incurred approximately $2.5 million in research and development expenses, contributing to its goal of addressing unmet medical needs in rare disease therapeutics.
Focus on Rare Diseases
The company's vision highlights a strong focus on rare diseases, which often lack effective treatment options. Quoin's pipeline includes QRX003 and QRX004, both targeting serious genetic conditions. The total estimated costs for the development of these products, including various clinical studies, is projected to be around $5.23 million.
Partnerships and Collaborations
Quoin Pharmaceuticals actively seeks strategic partnerships to enhance its research capabilities. Notable collaborations include agreements with Queensland University of Technology for research programs totaling approximately $610,000. Such collaborations are integral to the company’s vision of leveraging external expertise to expedite drug development.
Financial Performance and Growth Strategy
Financially, Quoin Pharmaceuticals reported a net loss of approximately $6.65 million for the nine months ended September 30, 2024. The company has a cash position of approximately $3.1 million and investments totaling $7.2 million, positioning itself for future growth and operational sustainability. The strategy focuses on raising additional capital through public offerings and collaborations, with a recent commitment of up to $8 million from Alumni Capital LP.
Table: Financial Overview of Quoin Pharmaceuticals (2024)
| Financial Metric | Value (2024) |
|---|---|
| Net Loss (Nine Months) | $6,651,198 |
| Research and Development Expenses (Nine Months) | $2,532,468 |
| Cash and Cash Equivalents | $3,116,750 |
| Investments in Marketable Securities | $7,200,000 |
| Estimated Development Costs for QRX003 | $4,400,000 |
| Estimated Development Costs for QRX004 | $830,000 |
Long-term Vision and Market Impact
Quoin Pharmaceuticals envisions becoming a pivotal player in the biopharmaceutical market by addressing the needs of patients suffering from rare diseases. This long-term vision is aimed at not only improving patient outcomes but also enhancing shareholder value through strategic investments and innovative product offerings.
Core Values of Quoin Pharmaceuticals, Ltd. (QNRX)
Integrity
Integrity is at the core of Quoin Pharmaceuticals’ operations. The company prioritizes ethical practices in all its dealings, establishing trust with stakeholders including employees, customers, and investors.
Quoin demonstrates its commitment to integrity through transparent communication regarding its financial health and clinical trial results. For instance, the company reported a net loss of approximately $6.65 million for the nine months ended September 30, 2024. This transparency fosters trust and aligns with the company's core value of integrity.
Innovation
Innovation drives Quoin Pharmaceuticals’ research and development efforts. The company focuses on developing treatments for rare and orphan diseases that currently lack effective therapies.
As of September 30, 2024, Quoin's lead product, QRX003, is under development as a potential treatment for Netherton Syndrome, with significant investment in clinical trials. The company incurred approximately $2.53 million in research and development expenses during the nine months ended September 30, 2024, reflecting a commitment to innovative solutions.
Collaboration
Collaboration is vital in Quoin Pharmaceuticals’ strategy to advance its research initiatives. The company has established partnerships with academic institutions to enhance its research capabilities.
Quoin entered into a research agreement with Queensland University of Technology for approximately $250,000 to develop a product targeting Netherton Syndrome. Additionally, a partnership with University College Cork involves funding of up to approximately $608,000 for the development of novel topical formulations. These collaborations illustrate Quoin's commitment to teamwork and leveraging external expertise.
Accountability
Accountability is emphasized in Quoin Pharmaceuticals’ corporate governance. The company holds itself accountable to its stakeholders through regular financial disclosures and adherence to regulatory requirements.
As of September 30, 2024, Quoin reported total liabilities of approximately $5.95 million and an accumulated deficit of $52.85 million. By providing stakeholders with detailed financial performance metrics, the company showcases its commitment to accountability and responsible management of resources.
Commitment to Patients
Commitment to patients is central to Quoin Pharmaceuticals’ mission. The company is dedicated to developing effective treatments for patients suffering from rare diseases.
Quoin’s ongoing clinical studies for QRX003 exemplify this commitment, with patient dosing having commenced in December 2022. The company’s focus on addressing unmet medical needs reflects its dedication to improving patient outcomes and quality of life.
| Core Value | Description | Recent Financial Data |
|---|---|---|
| Integrity | Ethical practices and transparency in operations | Net loss of $6.65 million for nine months ended September 30, 2024 |
| Innovation | Focus on developing treatments for rare diseases | $2.53 million in R&D expenses for nine months ended September 30, 2024 |
| Collaboration | Partnerships with academic institutions | $250,000 research agreement with Queensland University of Technology |
| Accountability | Corporate governance and stakeholder communication | Total liabilities of approximately $5.95 million |
| Commitment to Patients | Focus on patient outcomes and quality of life | Patient dosing for QRX003 commenced in December 2022 |
Quoin Pharmaceuticals, Ltd. (QNRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Quoin Pharmaceuticals, Ltd. (QNRX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Quoin Pharmaceuticals, Ltd. (QNRX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Quoin Pharmaceuticals, Ltd. (QNRX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.